BAYONNE, N.J., Sept. 16, 2026 (GLOBE NEWSWIRE) — BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock for total gross proceeds of $85,250,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering is expected to close on September 18, 2026, subject to satisfaction of customary closing conditions.

The Company granted the underwriter a 30-day option to purchase 1,650,000 additional shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions.

Piper Sandler & Co. is acting as the sole book-running manager for the offering.

The Company intends to use the net proceeds of this offering of common stock for general corporate purposes, including maintaining liquidity, funding working capital needs, supporting Bank capital including in connection with the expected disposition of identified potential problem loans, reducing debt, and maintaining the Company’s capital and liquidity ratios, and the capital and liquidity ratios of the Bank, at acceptable levels.

The offering of common stock is being made pursuant to a registration statement on Form S-3 (File No. 333-298337) that was declared effective by the Securities and Exchange Commission (the “SEC”) on August 25, 2026. A preliminary prospectus supplement to which this communication relates has been filed with the SEC. Prospective investors should read the preliminary prospectus supplement and the accompanying prospectus and other documents the Company has filed with the SEC for more complete information about the Company and the offering. Copies of these documents are available at no charge by visiting the SEC’s website at www.sec.gov. Alternatively, when available, copies of the preliminary prospectus supplement, the prospectus supplement and accompanying prospectus related to the offering may be obtained by contacting Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.

This press release does not constitute an offer to sell, a solicitation of an offer to sell, or the solicitation of an offer to buy any securities. There will be no sale of securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About BCB Bancorp, Inc.

Established in 2000 and headquartered in Bayonne, N.J., BCB Community Bank is the wholly-owned subsidiary of BCB Bancorp, Inc. (NASDAQ: BCBP). The Bank has twenty-two branch offices in Bayonne, Edison, Hoboken, Fairfield, Holmdel, Jersey City, Lyndhurst, Maplewood, Monroe Township, Newark, Plainsboro, River Edge, Rutherford, South Orange, Union, and Woodbridge, New Jersey, and four branches in Hicksville and Staten Island, New York. The Bank provides businesses and individuals a wide range of loans, deposit products, and retail and commercial banking services. For more information, please go to www.bcb.bank.

Forward-Looking Statements

This release, like many written and oral communications presented by BCB Bancorp, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. You can also identify them by the fact that they do not relate strictly to historical or current facts.

Forward-looking statements include statements with respect to our belief, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, including our growth strategy and expansion plans, including potential acquisitions. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.

Factors that could cause future results to differ materially from those anticipated by our forward-looking statements include the global impact of the United States military conflict with Iran, the periodic Federal budget and funding stalemates in Congress, global tariffs imposed by the Trump administration, higher inflation levels, changes in market interest rates and general economic concerns, all of which could impact our customers’ businesses and the economy and could cause increased loan delinquencies, a reduction in financial transactions and business activities, including decreased deposits and reduced loan originations. Other factors that could cause future results to vary materially from current management expectations as reflected in our forward-looking statements include, but are not limited to: global economic trends and geopolitical risks, including the ongoing conflicts in the Middle East, and changes in the rate of investment or economic growth, including as a result of sanctions, tariffs or other measures; unfavorable economic conditions in the United States generally and particularly in our primary market area and those of our customers, including the periodic Federal budget and funding stalemates in the U.S. Congress; the impact of changes in interest rates and the credit quality and strength of underlying collateral and the effect of such changes on the market value of our loan and investment securities portfolios; the credit risk associated with our loan portfolio; supply chain disruptions and labor shortages; the impact of any future pandemics or other natural disasters; the Company’s ability to effectively attract and deploy deposits; changes in the Company’s corporate strategies, the composition of its assets, or the way in which it funds those assets; the Company’s implementation of anticipated loan sales, which may not be completed in accordance with expected plans or the currently contemplated timeline, or at all, and may be disruptive to the Company and/or reduce the Company’s profitability in future periods; the pending sale of the Company’s cannabis business, which may not be completed in accordance with expected plans or the currently contemplated timeline, or at all, and may be disruptive to the Company and/or reduce the Company’s profitability in future periods; our ability to complete our proposed reincorporation from New Jersey to Delaware, including our ability to receive shareholder approval of the proposed reincorporation, and our ability to realize the anticipated benefits of the proposed reincorporation; shifts in investor sentiment or behavior in the securities, capital, or other financial markets, including changes in market liquidity or volatility; the effects of declines in real estate values that may adversely impact the collateral underlying our loans; increase in unemployment levels and slowdowns in economic growth; changes in the credit performance of our loan portfolio, including levels of criticized and classified loans, nonaccrual loans, and charge-offs; changes in the quality and composition of the Bank’s loan and investment portfolios; deposit flows; changes in liquidity levels, funding sources, or funding costs, and our ability to manage our liquidity risks; legislative and regulatory changes, including but not limited to, increases in Federal Deposit Insurance Corporation (“FDIC”) insurance rates; monetary and fiscal policies of the federal and state governments, including changes in government priorities or budgets; changes in tax policies, rates and regulations of federal, state and local tax authorities; demands for our loan products; demand for financial services; competition; changes in the securities or secondary loan markets; changes in management’s business strategies; our ability to enter new markets successfully; our ability to successfully integrate acquired businesses; changes in consumer spending; our ability to retain key employees; the effects of any reputational, credit, interest rate, market, operational, legal, liquidity, or regulatory risk; potential impact of regulatory requirements, matters, litigation, or other legal actions which could adversely affect operating results; failure to identify and adequately and promptly address cybersecurity risks, including data breaches and cyberattacks; developments in technology, such as artificial intelligence, and our ability to incorporate innovative technologies in our business and provide products and services that satisfy our customers’ expectations for convenience and security; civil unrest in the communities that we serve; changes in accounting principles and guidelines; other economic, competitive, governmental, regulatory, geopolitical and technological factors affecting our operations, pricing and services; and other factors discussed in other reports we filed with the SEC, including under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K filed for the year ended December 31, 2025, as updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and our other periodic reports that we file with the SEC.

CONTACT:    JAWAD CHAUDHRY,
     EVP, CFO & TREASURER
     (800) 680-6872

In a release issued under the same headline earlier today by Osisko Critical Minerals Corporation (OTCQX: OMZNF; FRANKFURT: 0B51), please note that a correction has been made in the second paragraph. The word “are” in the first sentence of the CEO’s comment was removed. The corrected release follows:

Gross Proceeds of $100,000,000 to Fund Exploration and Development of New Brunswick Properties

Special Warrants Priced at $0.25 per Special Warrant

Canaccord Genuity to Act as Lead Agent and Sole Bookrunner

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — Osisko Critical Minerals Corporation (“OCMC” or the “Corporation“), a newly incorporated entity and a wholly-owned subsidiary of Osisko Metals Incorporated (“Osisko Metals“) (TSX: OM; OTCQX: OMZNF; FRANKFURT: 0B51), is pleased to announce a best efforts private placement (the “Private Placement“) of special warrants of the Corporation (the “Special Warrants“) at a price of $0.25 per Special Warrant for gross proceeds of $100,000,000. The Private Placement will be led by Canaccord Genuity Corp. (“Canaccord Genuity“), acting as lead agent and sole bookrunner, on behalf of a syndicate of agents (collectively, the “Agents“).

Incoming CEO John Burzynski commented: “We have had a tremendous reception for OCMC in the capital markets, and the strong investor interest in our new critical minerals company reflects confidence in our exploration portfolio and the significant opportunity we see in New Brunswick. We look forward to completing this offering to capitalize this new venture and to advancing our aggressive exploration program on these highly prospective copper assets.”

Private Placement Terms

Upon satisfaction of the release conditions described below (the “Release Conditions“), each Special Warrant shall automatically convert, without payment of additional consideration, into one unit of the Corporation (each, a “Unit“), with each Unit consisting of one common share of the Corporation (each, a “Common Share“) and one-half of one common share purchase warrant of the Corporation (each whole warrant, a “Warrant“). Each Warrant will entitle the holder to acquire one Common Share at an exercise price of $0.35 per share for a period of 24 months following the closing date of the Private Placement (the “Closing Date“).

The Release Conditions shall mean (i) the receipt for a final prospectus (the “Qualifying Prospectus“) qualifying the distribution of the Common Shares and Warrants underlying the Special Warrants being issued by the securities regulatory authorities in the provinces of Canada in which the Special Warrants are sold; and (ii) the TSX Venture Exchange (the “Exchange“) granting conditional approval to list the Common Shares and Warrants, on or before the date that is 180 days following the Closing Date.

The Corporation intends to use the net proceeds of the Private Placement to fund: (i) exploration and development costs of the properties located in New Brunswick, Canada (the “Properties“); and (ii) general working capital and corporate expenses.

The Private Placement is expected to close on or about November 17, 2026 or such other date as may be mutually agreed upon between Canaccord Genuity and the Corporation (the “Closing Date“).

The Corporation shall use its best efforts to satisfy the Release Conditions as soon as practicable following the Closing Date.

New Brunswick Properties

The Properties comprise an aggregate of 2,972 mineral claim units (approximately 645 square kilometres) staked by the Osisko Metals and claims which it has an option to acquire pursuant to three separate option agreements (collectively, the “Option Agreements“, entered into on January 9, 2026; April 20, 2026; and September 9, 2026 respectively). In connection with the transaction, the Option Agreements will be assigned to the Corporation in exchange for common shares of Corporation. The Properties include several large-scale mineral exploration targets prospective for copper, silver and gold, underlain by highly prospective geology similar in context to the nearby Gaspé Copper Project, and are more particularly described in the news release of Osisko Metals dated September 15, 2026 and titled “Osisko Metals to Create New Critical Minerals Company”.

Additional Information

Bennett Jones LLP is acting as legal advisors to the Corporation in connection with the Go-Public Transaction.

Cassels Brock & Blackwell LLP is acting as legal advisors to the Agents in connection with the Private Placement.

Additional Information

There is no certainty that the Private Placement will be completed on the terms proposed, or at all. Completion of the Private Placement is subject to a number of conditions, including: completion of legal and tax structuring; completion of financial analysis; negotiation and execution of definitive documentation; and required regulatory approvals. There can be no assurance that any securities of the Corporation will be listed on any stock exchange.

Scientific and Technical Disclosure

Qualified Person

The scientific and technical information within this news release was reviewed and approved by Jared Hansen, P.Geo., a “qualified person” within the meaning of NI 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) who is not independent of Osisko Metals for purposes of Section 1.5 of NI 43-101.

About Osisko Critical Minerals Corporation

Osisko Critical Minerals Corporation is a newly incorporated Canadian mineral exploration company focused on the discovery and development of copper and critical minerals deposits. The Corporation’s principal assets are the Properties, comprising approximately 645 square kilometres of mineral claims in northern New Brunswick, Canada. The Properties include the NB Copper Project, which hosts large-scale exploration targets for bulk-tonnage copper deposits in a geological setting analogous to the nearby Gaspé Copper Project. OCMC is led by John Burzynski as Chief Executive Officer and is a wholly-owned subsidiary of Osisko Metals Incorporated pending completion of the Private Placement.

For further information on this news release, contact:

Don Njegovan, President
Email: info@osiskometals.com
Phone: (416) 500-4129

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Any statement that involves predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always, using phrases such as “expects” or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “potential”, “feasibility”, “believes” or “intends”, or variations of such words and phrases, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This news release contains forward-looking information pertaining to, among other things: statements with respect to the terms, timing and outcome of the Private Placement, including the expected closing date; that the Corporation will use the proceeds from the Private Placement to fund exploration and development of the Properties and general working capital; the timing of the satisfaction of the Release Conditions; the anticipated listing of the Common Shares and Warrants on the TSX Venture Exchange; the pre-closing steps to be completed by Osisko Metals, including the transfer of the Properties and the subscription for Units; Osisko Metals’ retention of an interest in the Corporation; receipt of the required regulatory approvals in connection with the Private Placement; the anticipated benefits of the Private Placement; anticipated strategic and growth opportunities; and the future plans and objectives of the Corporation.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including, without limitation, assumptions about: completion of the Private Placement, including the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary approvals for the Private Placement; completion of the Go-Public Transaction and satisfaction of the Release Conditions within the required timeframe; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Private Placement; that the anticipated benefits of the Private Placement will be realized; that general business and economic conditions will not change in a material adverse manner; that financing will be available if and when needed and on reasonable terms; that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Corporation’s planned exploration activities will be available on reasonable terms and in a timely manner; the ability of exploration results, including drilling, to accurately predict mineralization; errors in geological modelling; insufficient data; equity and debt capital markets; future spot prices of minerals; the timing and results of exploration and drilling programs; production costs; political and regulatory stability; the receipt of governmental and third party approvals; licenses and permits being received on favourable terms; sustained labour stability; stability in financial and capital markets; availability of mining equipment and positive relations with local communities and groups. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information are set out in Osisko Metals’ public disclosure record on SEDAR+ (www.sedarplus.ca) under Osisko Metals’ issuer profile.

Although Osisko Metals believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Osisko Metals disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

CALGARY, Alberta, Sept. 16, 2026 (GLOBE NEWSWIRE) — Computer Modelling Group Ltd. (“CMG” or the “Company”) (TSX: CMG) is pleased to announce that, in connection with its ongoing substantial issuer bid (the “SIB”) to purchase for cancellation up to C$20,000,000 in value of its common shares (the “Shares”), the Alberta Securities Commission, as CMG’s principal regulator, has granted an exemptive relief order exempting CMG from complying with certain extension take up, proportionate take up and related disclosure requirements. The exemptive relief applies in all jurisdictions of Canada.

The SIB is being made by way of a “modified Dutch auction”, allowing shareholders who choose to participate in the SIB to tender Shares in three ways:

  • by making an auction tender pursuant to which they agree to tender a specified number of Shares to CMG at a specified price per Share (an “Auction Price”) within a price range of C$4.00 (the “Minimum Purchase Price”) and C$4.50 in increments of C$0.10 per Share (an “Auction Tender”);
  • by making a purchase price tender, pursuant to which they do not specify a price per Share, but rather agree to have a specified number of Shares purchased at the Purchase Price (as defined below) to be determined by the Auction Tenders (a “Purchase Price Tender”); or
  • by making a proportionate tender, pursuant to which they tender all of the Shares they hold, at the Purchase Price to be determined pursuant to the SIB, on the basis that CMG will only purchase such number of Shares so tendered that will result in the shareholders maintaining their proportionate Share ownership in CMG following the completion of the SIB (a “Proportionate Tender”).

Upon expiry of the SIB, CMG will determine the lowest price per Share (which will not be more than C$4.50 per Share and not less than C$4.00 per Share) that will enable it to purchase all of the Shares collectively tendered pursuant to Auction Tenders at Auction Prices less than or equal to that price and Purchase Price Tenders, having an aggregate purchase price that does not exceed the Auction Tender Limit Amount (as defined below) (the “Purchase Price”); provided that if the aggregate purchase price for Shares collectively tendered pursuant to Auction Tenders at Auction Prices equal to the Minimum Purchase Price and Purchase Price Tenders exceeds the Auction Tender Limit Amount, the Purchase Price will be the Minimum Purchase Price. The term “Auction Tender Limit Amount” means the amount equal to: (a) $20,000,000 less, (b) the product of (i) $20,000,000 and (ii) a fraction, the numerator of which is the aggregate number of Shares owned by shareholders making valid Proportionate Tenders, and the denominator of which is the aggregate number of Shares outstanding at the Expiration Date (as defined below).

The SIB is not conditional upon any minimum number of Shares being tendered. The SIB is, however, subject to other conditions described in the formal offer to purchase and issuer bid circular, letter of transmittal and notice of guaranteed delivery (collectively, the “Offer Documents”), filed by CMG with the applicable securities regulators and available under CMG’s SEDAR+ profile at www.sedarplus.ca.

The SIB is currently open for acceptance until 5:00 PM (Eastern time) on September 21, 2026 (such time on such date, the “Expiration Date”), unless withdrawn, extended or varied by CMG. CMG reserves the right (i) to terminate the SIB and not take up and pay for any Shares not theretofore taken up and paid for, upon the occurrence of certain conditions, and (ii) at any time or from time to time, to vary the SIB in any respect, including increasing or decreasing the aggregate purchase price for Shares that the Company may purchase or the range of prices it may pay pursuant to the SIB, subject to compliance with applicable Canadian and United States securities laws and regulations.

As described in the Offer Documents, CMG applied for exemptive relief from the requirements under applicable securities laws: (i) to take up and pay for Shares deposited pursuant to the SIB proportionately according to the number of Shares deposited by each shareholder (the “Proportionate Take Up Relief”); (ii) to provide disclosure of the proportionate take up and payment of Shares under the SIB in CMG’s issuer bid circular in connection with the SIB (the “Proportionate Take Up Disclosure Relief”); and (iii) that an issuer bid not be extended if all the terms and conditions of the issuer bid have been complied with or waived unless the issuer first takes up all securities deposited under the issuer bid and not withdrawn (the “Extension Take Up Relief”, collectively, with the Proportionate Take Up Relief and the Proportionate Take Up Disclosure Relief, the “Issuer Bid Relief”). On September 15, 2026, the relevant securities regulatory authorities granted CMG the Issuer Bid Relief, which permits shareholders to tender to the SIB via Proportionate Tenders and which will allow CMG to, subject to the conditions in the exemptive relief order, elect to extend the SIB without first taking up all the Shares deposited and not withdrawn under the SIB.

At this time, CMG has not yet determined if it will extend the SIB, and the expiration of the SIB remains the Expiration Date, which for greater certainty is 5:00 PM (Eastern time) on September 21, 2026. CMG will determine whether it will extend the expiration of the SIB beyond the Expiration Date once it determines how many Shares have been tendered (and not withdrawn) under the SIB and considers all other relevant circumstances. In the event the SIB is extended, CMG will provide a further news release disclosing the details of such extension.

CMG has engaged National Bank Financial Inc. to act as the financial advisor and dealer manager (the “Dealer Manager”) for the SIB, and Olympia Trust Company to act as depositary (the “Depositary”). Any questions or requests for information regarding the SIB may be directed to the Depositary, at 1-833-684-1546 (Toll Free – North America), (587) 774-2340 or corporateactions@olympiatrust.com, or to the Dealer Manager, at 1-416-524-9514.

This news release is for informational purposes only and is not intended to and does not constitute an offer to purchase or the solicitation of an offer to sell Shares. The solicitation and the SIB are only being made pursuant to the Offer Documents filed with securities regulatory authorities. The SIB is not to be made to, nor will tenders be accepted from or on behalf of, holders of Shares in any jurisdiction in which the making or acceptance of offers to sell Shares would not be in compliance with the laws of that jurisdiction. The board of directors of CMG has approved the SIB; however, none of CMG, its board of directors, the Dealer Manager or the Depositary makes any recommendation to shareholders as to whether to tender or refrain from tendering any or all of their Shares to the SIB, whether shareholders should elect an Auction Tender, Purchase Price Tender or Proportionate Tender, or the purchase price or prices at which shareholders may choose to tender Shares. SHAREHOLDERS ARE STRONGLY URGED TO CAREFULLY READ THE OFFER DOCUMENTS AND RELATED DOCUMENTS FILED WITH SECURITIES REGULATORY AUTHORITIES, AS THEY MAY BE AMENDED FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Shareholders may obtain free copies of the Offer Documents filed by CMG with the applicable securities regulators and available under CMG’s profile on SEDAR+ at www.sedarplus.ca. Shareholders may also obtain those materials from the Depositary, as further discussed in the Offer Documents. Shareholders are urged to carefully evaluate all information in the Offer Documents, consult their own financial, legal, investment, accounting and tax advisors and make their own decisions as to whether to deposit Shares under the SIB and, if so, how many such Shares to deposit and at what price or prices.

Forward-Looking Information

Certain information in this press release may constitute “forward-looking information” within the meaning of applicable securities legislation. All information contained in this press release, other than statements of current and historical fact, is forward-looking information, including statements regarding the Company’s intentions and expectations with respect to the SIB, the terms and conditions of the SIB, the Expiration Date and the potential for extension, withdrawal or variation of the SIB, the actual number of Shares to be taken up and paid for in connection with the SIB, the Purchase Price, the aggregate purchase price for all Shares taken up, and other statements that are not historical facts (collectively, “forward-looking information”). Generally, forward-looking information can be identified by use of words such as “may”, “will”, “expect”, “believe”, “anticipate”, “estimate”, “intend”, “plan”, “would”, “could”, “should”, “continue”, “goal”, “objective”, “remain” and other similar terminology.

Forward-looking information is not, and cannot be, a guarantee of future results or events. Forward-looking information is necessarily based on a number of opinions, estimates, and assumptions that the Company considered appropriate and reasonable as of the date such statements are made. Although the forward-looking information contained herein is based upon what the Company believes are reasonable assumptions, actual results may vary from the forward-looking information contained herein. Certain assumptions made in preparing the forward-looking information contained herein include, without limitation: the Company’s future growth, cash flow generation, results of operations, trends in software licence sales, development plans and the status of the Company’s software development projects, future capital and other expenditures (including the amount, nature and sources of funding thereof), availability of government grants, competitive advantages, plans for and results of research and development activity, the availability of qualified personnel and general business strategies, prospects and opportunities. Additional assumptions include receipt of all requisite approvals and exemptions in connection with the Offer; favourable market conditions; and the absence of changes to applicable laws, regulations or policies affecting issuer bids. Inherent in the forward-looking information are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking information. Details of these risks are described in the Company’s annual publicly filed documents, including the Annual Information Form for the year ended March 31, 2026 (which are available on the Company’s profile on SEDAR+ at www.sedarplus.ca).

Investors should not place undue reliance on forward-looking information as a prediction of actual results. The forward-looking information reflects management’s current expectations and beliefs regarding future events and operating performance and is based on information currently available to management. Although we have attempted to identify important factors that could cause actual results to differ materially from the forward-looking information contained herein, there are other factors that could cause results not to be as anticipated, estimated or intended. The forward-looking information contained herein is current as of the date of this press release and, except as required under applicable law, we do not undertake to update or revise it to reflect new events or circumstances. Additionally, we undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of CMG, our financial or operating results, or our securities.

About CMG

CMG (TSX: CMG) is a global software and consulting company that combines science and technology with deep industry expertise to solve complex subsurface and surface challenges for the energy industry around the world. CMG is headquartered in Calgary, AB, with offices globally. For more information, visit www.cmgl.ca.

CONTACT: For investor inquiries, please contact:

Kim MacEachern
Director, Investor Relations
cmg-investors@cmgl.ca.

For media inquiries, please contact: marketing@cmgl.ca.

Gross Proceeds of $100,000,000 to Fund Exploration and Development of New Brunswick Properties

Special Warrants Priced at $0.25 per Special Warrant

Canaccord Genuity to Act as Lead Agent and Sole Bookrunner

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — Osisko Critical Minerals Corporation (“OCMC” or the “Corporation“), a newly incorporated entity and a wholly-owned subsidiary of Osisko Metals Incorporated (“Osisko Metals“) (TSX: OM; OTCQX: OMZNF; FRANKFURT: 0B51), is pleased to announce a best efforts private placement (the “Private Placement“) of special warrants of the Corporation (the “Special Warrants“) at a price of $0.25 per Special Warrant for gross proceeds of $100,000,000. The Private Placement will be led by Canaccord Genuity Corp. (“Canaccord Genuity“), acting as lead agent and sole bookrunner, on behalf of a syndicate of agents (collectively, the “Agents“).

Incoming CEO John Burzynski commented: “We are have had a tremendous reception for OCMC in the capital markets, and the strong investor interest in our new critical minerals company reflects confidence in our exploration portfolio and the significant opportunity we see in New Brunswick. We look forward to completing this offering to capitalize this new venture and to advancing our aggressive exploration program on these highly prospective copper assets.”

Private Placement Terms

Upon satisfaction of the release conditions described below (the “Release Conditions“), each Special Warrant shall automatically convert, without payment of additional consideration, into one unit of the Corporation (each, a “Unit“), with each Unit consisting of one common share of the Corporation (each, a “Common Share“) and one-half of one common share purchase warrant of the Corporation (each whole warrant, a “Warrant“). Each Warrant will entitle the holder to acquire one Common Share at an exercise price of $0.35 per share for a period of 24 months following the closing date of the Private Placement (the “Closing Date“).

The Release Conditions shall mean (i) the receipt for a final prospectus (the “Qualifying Prospectus“) qualifying the distribution of the Common Shares and Warrants underlying the Special Warrants being issued by the securities regulatory authorities in the provinces of Canada in which the Special Warrants are sold; and (ii) the TSX Venture Exchange (the “Exchange“) granting conditional approval to list the Common Shares and Warrants, on or before the date that is 180 days following the Closing Date.

The Corporation intends to use the net proceeds of the Private Placement to fund: (i) exploration and development costs of the properties located in New Brunswick, Canada (the “Properties“); and (ii) general working capital and corporate expenses.

The Private Placement is expected to close on or about November 17, 2026 or such other date as may be mutually agreed upon between Canaccord Genuity and the Corporation (the “Closing Date“).

The Corporation shall use its best efforts to satisfy the Release Conditions as soon as practicable following the Closing Date.

New Brunswick Properties

The Properties comprise an aggregate of 2,972 mineral claim units (approximately 645 square kilometres) staked by the Osisko Metals and claims which it has an option to acquire pursuant to three separate option agreements (collectively, the “Option Agreements“, entered into on January 9, 2026; April 20, 2026; and September 9, 2026 respectively). In connection with the transaction, the Option Agreements will be assigned to the Corporation in exchange for common shares of Corporation. The Properties include several large-scale mineral exploration targets prospective for copper, silver and gold, underlain by highly prospective geology similar in context to the nearby Gaspé Copper Project, and are more particularly described in the news release of Osisko Metals dated September 15, 2026 and titled “Osisko Metals to Create New Critical Minerals Company”.

Additional Information

Bennett Jones LLP is acting as legal advisors to the Corporation in connection with the Go-Public Transaction.

Cassels Brock & Blackwell LLP is acting as legal advisors to the Agents in connection with the Private Placement.

Additional Information

There is no certainty that the Private Placement will be completed on the terms proposed, or at all. Completion of the Private Placement is subject to a number of conditions, including: completion of legal and tax structuring; completion of financial analysis; negotiation and execution of definitive documentation; and required regulatory approvals. There can be no assurance that any securities of the Corporation will be listed on any stock exchange.

Scientific and Technical Disclosure

Qualified Person

The scientific and technical information within this news release was reviewed and approved by Jared Hansen, P.Geo., a “qualified person” within the meaning of NI 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) who is not independent of Osisko Metals for purposes of Section 1.5 of NI 43-101.

About Osisko Critical Minerals Corporation

Osisko Critical Minerals Corporation is a newly incorporated Canadian mineral exploration company focused on the discovery and development of copper and critical minerals deposits. The Corporation’s principal assets are the Properties, comprising approximately 645 square kilometres of mineral claims in northern New Brunswick, Canada. The Properties include the NB Copper Project, which hosts large-scale exploration targets for bulk-tonnage copper deposits in a geological setting analogous to the nearby Gaspé Copper Project. OCMC is led by John Burzynski as Chief Executive Officer and is a wholly-owned subsidiary of Osisko Metals Incorporated pending completion of the Private Placement.

For further information on this news release, contact:

Don Njegovan, President
Email: info@osiskometals.com
Phone: (416) 500-4129

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Any statement that involves predictions, expectations, interpretations, beliefs, plans, projections, objectives, assumptions, future events or performance (often, but not always, using phrases such as “expects” or “does not expect”, “is expected”, “interpreted”, “management’s view”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “potential”, “feasibility”, “believes” or “intends”, or variations of such words and phrases, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and may be forward-looking information and are intended to identify forward-looking information. This news release contains forward-looking information pertaining to, among other things: statements with respect to the terms, timing and outcome of the Private Placement, including the expected closing date; that the Corporation will use the proceeds from the Private Placement to fund exploration and development of the Properties and general working capital; the timing of the satisfaction of the Release Conditions; the anticipated listing of the Common Shares and Warrants on the TSX Venture Exchange; the pre-closing steps to be completed by Osisko Metals, including the transfer of the Properties and the subscription for Units; Osisko Metals’ retention of an interest in the Corporation; receipt of the required regulatory approvals in connection with the Private Placement; the anticipated benefits of the Private Placement; anticipated strategic and growth opportunities; and the future plans and objectives of the Corporation.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including, without limitation, assumptions about: completion of the Private Placement, including the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary approvals for the Private Placement; completion of the Go-Public Transaction and satisfaction of the Release Conditions within the required timeframe; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Private Placement; that the anticipated benefits of the Private Placement will be realized; that general business and economic conditions will not change in a material adverse manner; that financing will be available if and when needed and on reasonable terms; that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Corporation’s planned exploration activities will be available on reasonable terms and in a timely manner; the ability of exploration results, including drilling, to accurately predict mineralization; errors in geological modelling; insufficient data; equity and debt capital markets; future spot prices of minerals; the timing and results of exploration and drilling programs; production costs; political and regulatory stability; the receipt of governmental and third party approvals; licenses and permits being received on favourable terms; sustained labour stability; stability in financial and capital markets; availability of mining equipment and positive relations with local communities and groups. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information are set out in Osisko Metals’ public disclosure record on SEDAR+ (www.sedarplus.ca) under Osisko Metals’ issuer profile.

Although Osisko Metals believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Osisko Metals disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Swiss Water Decaffeinated Coffee Inc. (TSX:SWP) (“Swiss Water” or “the Company”) today announced it will invest $6.2 million to expand production capacity at its Delta, BC facility. The investment will increase production volume by 15% from its current maximum capacity.

Construction is expected to commence in Q1 2027 with no disruption to existing operations. The expansion is scheduled to be completed by June 2027 and operating commercially by July 2027. The Company anticipates internally financing the majority of the investment from operating cash flow, with the balance coming from existing credit lines.

“Decaffeinated coffee drinkers are increasingly demanding that their coffee contain no residual chemical solvents. This continues to drive an industry-wide migration away from chemical decaffeination processes in favour of 100% chemical free products like Swiss Water Process® coffees. In response, we are excited to announce that, due to growing demand for our decaffeinated coffee and rapidly expanding utilization of our existing production capacity, we will be investing in the expansion of our technologically advanced production facility. This expansion supports Swiss Water’s broader strategy to support existing customer demand, attract new trading partners, and expand into new markets,” said Frank Dennis, Swiss Water’s President & CEO.

Key Details of Expansion

• Investment: $6.2 million
• Location: Delta, BC
• Capacity Increase: 15%
• Completion Date: June, 2027
 

Company Profile

Swiss Water Decaffeinated Coffee Inc. is a leading specialty coffee company and a premium green coffee decaffeinator that employs the proprietary Swiss Water® Process to decaffeinate green coffee without the use of chemical solvents such as methylene chloride. It also owns Seaforth Supply Chain Solutions Inc., a green coffee handling and storage business. Both businesses are located in Delta, British Columbia, Canada.

Swiss Water Decaffeinated Coffee Inc. is a leading specialty coffee company and a premium green coffee decaffeinator which employs the proprietary SWISS WATER® Process to decaffeinate green coffee without the use of chemicals. It also owns Seaforth Supply Chain Solutions, a green coffee handling and storage business. Both businesses are located in the city of Delta, British Columbia.

For more information, please contact

Iain Carswell, Chief Financial Officer
Swiss Water Decaffeinated Coffee Inc.
Phone: 1-604-420-4050
Email: investor-relations@swisswater.com
Website: investor.swisswater.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking” statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. When used in this press release, such statements may include such words as “may”, “will”, “expect”, “believe”, “plan”, “anticipate” and other similar terminology. These statements reflect management’s current expectations regarding future events and operating performance, as well as management’s current estimates, which are based on numerous assumptions and may prove to be incorrect. These statements are neither promises nor guarantees but involve known and unknown risks and uncertainties, including, but not limited to, risks related to processing volumes and sales growth, operating results, the supply of utilities, the supply of coffee and packaging materials, supply of labour force, general industry conditions, commodity price risks, technology, competition, foreign exchange rates, construction timing, costs and financing of capital projects, a potential impact of any pandemics, global and local climate changes, changes in interest rates, inflation, transportation availability, and general economic conditions. The forward-looking statements and financial outlook information contained herein are made as of the date of this press release and are expressly qualified in their entirety by this cautionary statement. Except to the extent required by applicable securities law, Swiss Water undertakes no obligation to publicly update or revise any such statements to reflect any change in management’s expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those described.

TORONTO, ONTARIO, Sept. 16, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce, further to the press release dated September 10, 2026, the closing of the second tranche of a non-brokered private placement of the 15% unsecured convertible debentures (the “Offering”).

In the second tranche of the Offering, the Company issued additional unsecured convertible debentures (the “Debentures”) in an aggregate principal amount of US$4,375,000 million, for an aggregate principal amount, together with the first closing, of US$10,706,250. The terms of the Offering contemplate the issuance of an aggregate principal amount of Debentures up to US$20 million, and the Company anticipates closing one or more additional tranches in the coming weeks. Completion of additional tranches is subject to customary closing conditions, and there can be no assurance that additional tranches will be completed.

As previously disclosed, pursuant to the rules and policies of the Toronto Stock Exchange (the “TSX”), the conversion rights and certain related terms of the Debentures require shareholder approval. The Company has agreed to call a meeting of shareholders (the “Meeting”) within six months to seek the necessary approvals. Additional details will be provided in a forthcoming management information circular, which, once filed, will be available on SEDAR+ at www.sedarplus.ca.

In connection with the second tranche, the Company agreed to pay finders’ fees (a “Finder’s Fee”) on certain subscriptions, which Finder’s Fees may be satisfied in cash or through the issuance of Debentures. Total Finder’s Fees for the second tranche amounted to US$35,000 aggregate principal amount of Debentures and US$100,000 in cash. Any Debentures issued as Finder’s Fees are counted towards the aggregate principal amount outstanding, and the maximum of US$20,000,000.

The Debentures (and Common Shares issuable upon conversion of the Debentures) are subject to a four-month hold period under Canadian securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc. is a holding company operating through its subsidiaries, including Ceapro Inc. (“Ceapro”) and Nualtis™.

Ceapro is focused on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources, using proprietary manufacturing and extraction technologies. Ceapro’s primary active ingredient business activities relate to the development and commercialization of natural products for the personal care, cosmetic, human and animal health industries.

Nualtis is a specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies. Its business model includes pharmaceutical formulation development, analytical and regulatory support services, contract development and manufacturing activities, partner-sponsored development programs and commercial product manufacturing.

The Company’s common shares are listed on the TSX under the symbol “CSCI” and are listed and posted for trading on the OTCQB® Venture Market under the symbol “CSCIF”. For more information, please visit COSCIENS’ website at www.cosciensbio.com.

Forward-Looking Statements

Certain statements in this news release constitute “forward-looking statements” and/or “forward-looking information” under applicable securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Specific forward-looking statements in this document include, but are not limited to, statements relating to: the expectation of and timing to complete additional tranches of the Offering; the timing to hold the Meeting to receive any required approvals; and the plans, objectives, future outlook and financial position of the Company in general. All forward-looking statements are given pursuant to the “safe harbour” provisions of applicable securities legislation.

The forward-looking statements and financial outlook information contained in this news release are based on a number of material factors, expectations, assumptions and estimates made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, including, without limitation, assumptions regarding: the ability of the Company to complete additional tranches of the Offering and otherwise satisfy its ongoing operations and the availability of capital on acceptable terms; prevailing economic, market, industry and regulatory conditions; and the continued execution of the Company’s strategic plans.

Forward-looking statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statement. Such risk factors are included under “Risk Factors” in our Annual Report and in other documents furnished to the SEC and in our other public disclosure filed under our profile on SEDAR+ at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Many of these factors are beyond our control, and it is not possible for the Company to predict all of these factors, or to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements contained herein, except as required by applicable securities laws.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

Issuer Contact:
Peter H. Puccetti
Chief Executive Officer and Chairman of the Board
ppuccetti@cosciensbio.com

Giuliano La Fratta
Chief Financial Officer
glafratta@cosciensbio.com

Investor Contact:
IR@cosciensbio.com

Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround time

HOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today introduced the Fill-Tek™ Dispensing System. Fill-Tek is a proprietary single-use bag dispensing capability that fills an entire custom reagent order across multiple bag sizes and quantities as a single lot. The Fill-Tek system removes the per-bag-size minimums that come with fixed manifold designs, so manufacturers can order the formats their process calls for rather than the formats the fill line requires.

“Your process is one of a kind, and now your fill line can be, too,” said Stephen Gunstream, President and Chief Executive Officer. “Our new Fill-Tek Dispensing System is the latest evolution of our modular manufacturing platform, expanding our ability to truly meet our customers’ complex custom reagent needs. Previously, fixed manifold designs could constrain the number of single-use bags that could be filled as one lot. Our talented team of engineers developed Fill-Tek to remove that constraint entirely. Following the recent introduction of our AI-driven Build-Tek™ Custom Configurator, the launch of Fill-Tek demonstrates our team’s commitment to continued innovation across the entire custom order process to meet the ever-changing needs of our customers who develop and manufacture emerging therapies and diagnostics.”

With the Fill-Tek Dispensing System, customers can simply specify the various bag sizes and quantities across formats ranging from 250 mL to 200 L single-use bags, and then tailor fill volume, number, size, and sequence of QC samples, testing requirements, and connectors. Fill-Tek uses validated aseptic welds to connect the customer’s specific combination of single-use bags to a dispensing vessel so they can be filled from a single batch through a single filter, resulting in one Certificate of Analysis for each lot.

“The bioprocessing workflows and manufacturing requirements for novel therapeutics and diagnostics are complex and dynamic, and we’re committed to finding better ways to streamline and support them. Fill-Tek operates by formulating and dispensing from one batch vessel through one filter into the exact configurations that a customer may need, including a variety of bag sizes with different fill volumes, or even a single bag,” said Bella Neufeld, Teknova’s Vice President of Operations. “With Fill-Tek, we simplify incoming quality control requirements, enable the use of the same reagent in different volumes at different workflow stages, and minimize rework by attaching the right connectors onto the bags so they seamlessly integrate into an existing bioprocessing system.”

Fill-Tek runs in Teknova’s ISO-classified cleanrooms as part of the Company’s validated aseptic dispensing process, backed by its ISO 13485:2016 certified quality management system. The capability is available across Teknova’s RUO, RUO+, and GMP manufacturing grades, with batch volumes that start from eight liters for custom research-grade orders and 25 liters for GMP-grade orders, scaling up to 2,000 liters – all with no change to Teknova’s industry-leading turnaround times.

Fill-Tek is available today. To place a custom order, customers can use the Build-Tek Custom Configurator on Teknova’s website, email info@teknova.com, or call 1.800.209.4488.

For more information about the Fill-Tek Dispensing System, click here.

ABOUT TEKNOVA

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

This press release was published by a CLEAR® Verified individual.

CONTACT: CONTACTS

Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100

Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259

Stephen Willard

Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)
Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)

Company Announces Exploration of All Options to Maximize Shareholder Value

  • The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
  • Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron’s multiple clinical programs, and has shown potential efficacy in clinical studies across multiple indications and has received 5 designations from FDA
  • Laromestrocel has shown positive initial results in Aging-related Frailty, including publication of clinical trial results in Cell Stem Cell and selection as a Finalist awardee in the XPRIZE Healthspan global competition
  • The Company has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value

MIAMI, Sept. 16, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS). The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12. In the intent-to-treat (ITT) population, the least-squares mean difference between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336).

Initial exploratory clinical outcomes in the as-treated analyses include:

  • Over a 12-month period, there were no deaths in patients that received laromestrocel, compared to one patient in the control group, in the as-treated group
  • Over a long-term follow up of transplant-free survival (up to five years across all patients), the laromestrocel arm had one event (out of 17 patients) vs. two events (out of 21 patients) in the standard-of-care arm
  • Hospitalization burden was similar between arms
  • Adjudicated Major Adverse Cardiovascular Events (MACE) were approximately 31% fewer in the laromestrocel arm (12 events in the treated arm vs. 19 events in the untreated arm, respectively). However, the negative binomial analysis was not statistically significant.

A sponsor-defined exploratory hierarchical composite endpoint consisting of all-cause mortality and duration of inpatient hospitalization was not statistically significant in the ITT population.

Laromestrocel demonstrated a safety profile generally consistent with prior clinical trials, and no new safety signals were identified in the study.

The Company is conducting additional analyses of the complete dataset and intends to discuss the results with the U.S. Food and Drug Administration (FDA) to determine potential next steps for the HLHS development program. FDA previously indicated its willingness to meet with the Company following completion of the study to discuss the results and potential paths forward.

Sunjay Kaushal, M.D., Ph.D., Professor of Surgery, Cardiovascular and Thoracic Surgery at University of Nevada, Las Vegas commented: “There remains a significant unmet medical need to boost the survival of the babies undergoing standard of care surgeries that still have only a 50-60% survival rate to adolescence with approximately 20% requiring heart transplant. ELPIS II provides evidence of the safety of using stem cells to address this unmet need.”

Laromestrocel demonstrated a favorable safety and tolerability profile in ELPIS II, consistent with the safety experience observed across Longeveron’s clinical development programs, in which 644 participants have been treated to date. Treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) were reported in 94.1% and 64.7% of laromestrocel-treated participants, respectively, compared with 100% and 71.4% of control participants. No new safety signals were identified, and no TEAEs or TE-SAEs were assessed by investigators as related to laromestrocel.

The Company thanks the patients, families, investigators, and clinical sites who participated in the ELPIS II trial, as well as the NIH and the Data Coordinating and Clinical Coordinating Centers for their partnership throughout the study.

“Since its founding, Longeveron has advanced the stem cell therapy laromestrocel, completed multiple clinical trials and built a robust intellectual property portfolio,” said Stephen H. Willard, Chief Executive Officer of Longeveron. “The ELPIS II results continue to build our body of knowledge of laromestrocel for which we see significant promise across multiple indications, particularly in longevity and Aging-related Frailty. We will work with our advisors to evaluate all options to maximize shareholder value.”

Review of All Options to Maximize Shareholder Value
The Company announced that it has initiated a process to review all options with the goal of maximizing shareholder value. The Company intends to engage an investment bank to act as a strategic advisor for this process. In conjunction with that process, the Company will look to implement cash conservation measures to optimize cost containment.

Longevity and Aging-Related Frailty
The Company intends to pursue funding sources and other potential revenue opportunities to advance laromestrocel in longevity and Aging-related Frailty. Results from a Phase 2b clinical trial demonstrated that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. These results were published in Cell Stem Cell in February 2026. Further, based on these clinical trial results, Longeveron announced in August 2026 that it was selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron received the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million.

Longeveron has been invited to participate in six upcoming longevity focused investor conferences in the fourth quarter of 2026.

About ELPIS II
ELPIS II is a Phase 2b, randomized, double-blind, multicenter, two-arm trial conducted by Longeveron in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) through grants from the National Institutes of Health (NIH) (NCT04925024). A total of 40 infants with HLHS were randomized 1:1 to receive a single intramyocardial dose of laromestrocel administered during Stage 2 palliative surgery (bidirectional Glenn or hemi-Fontan procedure) or standard of care surgery alone, and were followed for 12 months. Long-term follow-up for transplant-free survival is planned for up to 5 years.

The trial’s primary endpoint was the difference between groups’ change from baseline in RVEF at 12 months, assessed by cardiac magnetic resonance (CMR). As previously disclosed, FDA has advised Longeveron that RVEF alone would not be sufficient to demonstrate efficacy for regulatory approval.  FDA also previously expressed willingness to meet with Longeveron when the ongoing study is completed to discuss the study results and align on a potential path forward.

Research reported in this press release was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number UH3HL148318. The content is solely the responsibility of the Company and does not necessarily represent the official views of the National Institutes of Health.

About Hypoplastic Left Heart Syndrome (HLHS)
HLHS is a rare congenital heart defect that effects approximately 1,000 infants per year in the U.S. Infants with HLHS are born with an underdeveloped left ventricle, which creates a life-threatening condition due to the heart’s inability to pump adequate amounts of blood throughout the body. The current treatment requires infants to undergo a complex three-stage heart reconstruction surgery process over the first five years of their life. Despite staged surgical palliation, long-term mortality and morbidity remain substantial, with progressive right ventricular dysfunction representing a major contributor to adverse outcomes. There is clearly an important unmet medical need to improve right ventricular function in these infants to positively impact both short- and long-term patient outcomes.

About laromestrocel (Lomecel-B®)
Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young, healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to the human endogenous biological repair mechanism. MSCs have the potential to perform a number of complex functions in the body and possibly support tissue repair and regenerative signaling pathways. They also may respond to sites of injury or disease and may secrete bioactive factors that are immunomodulatory and regenerative. We believe laromestrocel MSCs may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including discussion of ELPIS II results with the FDA and the future of the HLHS development program; our ability to pursue funding sources and potential revenue opportunities to advance laromestrocel in longevity and Aging-related frailty; our expectations regarding the review and exploration of all options and their potential impact on shareholder value; our ability to engage an investment bank or other strategic advisor; the continued listing of our Class A common stock on Nasdaq; our expectations regarding the future of the company’s operations, including our clinical, development and commercialization activities; our plans to implement cash conservation measures to reduce operating expenses; and other statements regarding future events. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,”  “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Additional factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the risk that the exploration of strategic options may not result in any definitive transaction or enhance shareholder value or may create uncertainty that may adversely affect our business, financial condition, results of operations, or shareholder and investor perception; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for laromestrocel in our development programs; our ability to reach alignment with the FDA and other regulatory authorities on a potential path toward regulatory approval; the availability of evidence from our ongoing and future preclinical studies and clinical trials sufficient to support the Company filing a BLA for the investigational product candidate for one or more indications; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;  the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in a highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Inquiries:
investorrelations@longeveron.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cde71c09-a5f1-424d-837b-80f8786d82a5

XTEND selected as a Gauntlet II leader in the Close Quarters Battle segment following successful delivery and demonstration of 120 STRIKER systems

TAMPA, Fla., Sept. 16, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND) today announced that it was selected as a top performer in the close quarters battle segment of Gauntlet II of the U.S. Department of War’s iterative $1 billion Drone Dominance Program (DDP).

The result follows XTEND’s successful delivery and demonstration of 120 STRIKER systems in operationally realistic scenarios evaluated by warfighters for Gauntlet II, and marks another significant milestone in the company’s growing role in U.S. defense programs.

“This is a major win for XTEND,” said Aviv Shapira, Co-Founder and CEO of XTEND. “We delivered, we competed, and we proved what STRIKER is capable of in the hands of U.S. warfighters. This achievement demonstrates the strength of our technology.”

STRIKER is powered by XTEND’s proprietary XOS operating system and is designed for tactical missions in confined, complex and GNSS-denied environments.

The $1 billion U.S. Department of War Drone Dominance Program is building a resilient, U.S.-based supply chain for low-cost, capable one-way attack drone systems, jointly managed by the Defense Innovation Unit (DIU) and the Test Resource Management Center (TRMC). Naval Surface Warfare Center, Crane Division (NSWC Crane) serves as the DDP contracting authority.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities of XOS and its STRIKER system and its financial prospects, including that according to the Drone Dominance Program the 10 companies selected for Gauntlet II are finalists for prototype contracts and awards are not guaranteed. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including the timing and size of orders from government and defense customers, geopolitical and economic conditions in the United States and the other regions in which XTEND operates, and the other risks described under “Risk Factors” in the registration statement on Form S-4 filed with the SEC in connection with the business combination and in XTEND’s other filings with the SEC, available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. XTEND does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About XTEND AI Robotics, Inc.

XTEND is a leader in software systems and Physical AI, deployed in high-threat, complex operational environments where human exposure carries significant risk. Powered by its proprietary XTEND Operating System (XOS), XTEND’s integrated software and advanced robotic hardware solutions are designed to provide autonomy at the edge. Operating across Defense, Homeland Security, and Commercial Security missions through a platform of robots, drones, and robotic subsystems, XTEND’s open architecture platform facilitates scalability across partners and third-party applications. With over 12,500 systems deployed in over 30 countries, XTEND’s solutions have been validated in five combat zones and operationally deployed by national defense, special-mission units, and security organizations across the globe. Founded in Tel Aviv, Israel, and headquartered in Tampa, Florida, XTEND delivers NDAA-compliant solutions through a global network of regional XFAB manufacturing facilities located in the U.S., the U.K., Singapore, Israel, Mexico and Latvia.

Contacts
XTEND Media Contact:
Headline Media
Sarah Small
929-255-1449
sarah@headline.media

XTEND Investor Relations:
MZ North America
Shannon Devine
203-741-8811
XTND@mzgroup.us

LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) — Preferred Bank (NASDAQ: PFBC), one of the larger independent commercial banks in California, today reported that the Board of Directors has declared a quarterly cash dividend of $0.80 per share, payable on October 19, 2026 to holders of record on October 5, 2026.

About Preferred Bank

Preferred Bank is one of the larger independent commercial banks headquartered in California. The Bank is chartered by the State of California, and its deposits are insured by the Federal Deposit Insurance Corporation, or FDIC, to the maximum extent permitted by law. The Bank conducts its banking business from its main office in Los Angeles, California, and through thirteen full-service branch banking offices in California (Alhambra, Century City, City of Industry, Torrance, Arcadia, Irvine (2), Diamond Bar, Pico Rivera, Tarzana and San Francisco (2)), Cupertino, two branches in New York (Manhattan and Flushing, Queens) and a branch office in the Houston, Texas suburb of Sugar Land. Preferred Bank offers a broad range of deposit and loan products and services to both commercial and consumer customers. The Bank provides personalized deposit services as well as real estate finance, commercial loans and trade finance to small and mid-sized businesses, entrepreneurs, real estate developers, professionals and high net worth individuals. Although originally founded as a Chinese-American Bank, Preferred Bank now derives most of its customers from the diversified mainstream market but does continue to benefit from the significant migration to California of ethnic Chinese from China and other areas of East Asia.

AT THE COMPANY: AT FINANCIAL PROFILES:
Edward J. Czajka Jeffrey Haas
Executive Vice President General Information
Chief Financial Officer (310) 622-8221
(213) 891-1188 PFBC@finprofiles.com
   

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.